Not finding it? Sign in to also search OpenAlex live.
-
MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
2citations -
Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
Deeksha Vishwamitra, Sheri Skerget, Kalpana K. Bakshi, Lien Vandenberk, Weili Sun, Jaszianne A. Tolbert, +26 more
2citations -
Long-Term Weight Changes After Starting Anti–IL-5/5Ra Biologics in Severe Asthma: The Role of Oral Corticosteroids2023 The Journal of Allergy and Clinical Immunology In Practice article Medicine Asthma and respiratory diseases Open access
Lianne ten Have, Edith Visser, Fleur L. Meulmeester, Sarah Bendien, Gert‐Jan Braunstahl, Marielle E.A.C. Broeders, +15 more
14citations -
Selection of patients for proton therapy to reduce risk of second primary lung and breast cancer2025 Radiotherapy and Oncology review Physics and Astronomy Radiation Therapy and Dosimetry Open access
Liesbeth Jorinne Boersma, Arno C. Hessels, Sander Roberti, Enrica Seravalli, Nina Bijker, Robert Paul Coppes, +22 more
6citations -
Evaluating the efficacy of different praziquantel treatment regimens using egg and circulating anodic antigen (CAA) detection methods in a Schistosoma mansoni endemic area in northeastern Brazil2025 International Journal for Parasitology Drugs and Drug Resistance article Immunology and Microbiology Parasites and Host Interactions Open access
Rosângela Lima de Freitas Galvão, Pytsje T. Hoekstra, Paul L. A. M. Corstjens, Marta Cristhiany Cunha Pinheiro, Ângela Maria da Silva, Luciene Barbosa, +3 more
3citations -
A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy2024 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Yuka Sugimoto, Eran Zimran, Yoshimitsu Shimomura, Hiroki Yamaguchi, Hans Carl Hasselbach, Jean‐Jacques Kiladjian, +14 more
2citations -
Large-scale field application of a fingerstick blood test for Mycobacterium leprae infection: Monitoring population-wide effects of case finding and post-exposure prophylaxis on transmission in the Comoros and Madagascar
Louise Pierneef, Sofie Marijke Braet, Daniëlle de Jong, Stéphanie Ramboarina, Anouk van Hooij, Merna Abdou, +13 more
2citations -
Real-Life Data of Cyclosporine (CsA) Tapering in Patients with Very/ Severe Aplastic Anemia (v/sAA) Treated with Horse Anti-Thymocyte Globulin (hATG/CsA) Suggest Higher Risk of AA Relapse at Cyclosporine Plasma Levels below 100 Nanogram per Milliliter2023 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Blood disorders and treatments
Jeanette Walter, Kim Kricheldorf, Yannic Schumacher, Susanne Isfort, Jörg Chromik, Beatrice Drexler, +4 more
2citations -
P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +11 more
1citations -
Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
Brendan Paul Hodkinson, Ashwini Kumar, Sheri Skerget, Gary E. Mason, Elizabeth Shearin, Hein Ludlage, +26 more
1citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
1citations -
Temporal trends of subsequent malignant neoplasms in childhood cancer survivors and the impact of treatment changes: a DCCSS-LATER study2026 JNCI Journal of the National Cancer Institute article Medicine Multiple and Secondary Primary Cancers Open access
Aimée S.R. Westerveld, Helena J. H. van der Pal, Joyce Wilbers, Andrica C. H. de Vries, Marloes Louwerens, Maria M.W. Koopman, +14 more
0citations